At a Boston longevity meeting, obesity drugs were pitched as aging drugs — here’s what the data actually show
·At this year’s ARDD longevity meeting in Boston, the world’s biggest obesity-drug makers did something new: they pitched their drugs as aging drugs. Eli Lilly showed data suggesting tirzepatide slows epigenetic aging clocks; Novo Nordisk reportedly claimed semaglutide reversed biological age by three to four years. It’s the first time big pharma has made the longevity case in public — and the evidence deserves a careful, mitochondria-aware look.
What was presented in Boston
Eli Lilly’s VP of Aging Research, Kevin Duffin, presented an epigenetic sub-study nested inside SURMOUNT-5, the head-to-head trial of tirzepatide versus semaglutide. With paired whole-blood samples at baseline and week 72 (1.38 years elapsed) from 82 unique subjects — 71 with paired data, 91.5% on the 15 mg dose — all 15 epigenetic clocks showed less aging than the elapsed time. Two clocks reached statistical significance, with median gains of 1.1 and 0.7 years; the DunedinPACE pace-of-aging clock fell from 1.13 to 1.08. An independent re-analysis by TruDiagnostic reproduced the direction of the effect. Duffin himself framed it as a small pilot to test methods — not a definitive result.
Novo Nordisk’s claim traveled a thinner path: per BiotechTV reporting, the company presented unpublished data showing semaglutide reversed biological age by 3–4 years in a very large study using proteomic clocks. Unpublished, relayed secondhand — that’s a claim, not evidence.
The mitochondria connection
Why does this belong on a mitochondria site? Because the proposed mechanism runs straight through cellular energy. A 2026 Aging Cell review, “The GLP-1–Mitochondria Axis in Metabolic Aging,” maps how GLP-1 receptor agonists affect mitochondrial biology — fuel switching, oxidative capacity, quality control. But the review states plainly that direct human mitochondrial and respirometric data are still missing. The mitochondrial story is plausible and actively being mapped — and unproven in people.
That missing link is the difference between “clocks ticked slower” and “these drugs rejuvenate your cells.” Epigenetic clocks are biomarkers, not function — and they can move with weight loss, reduced inflammation, and medication effects that have nothing to do with slowing aging itself.
Why we’re calling the evidence contested
Lilly’s data are a real, small, method-testing pilot — interesting, reproduced in direction by an independent lab, and far from proof. Novo’s is an unpublished conference claim. Neither shows that anyone’s mitochondria work better or that anyone lives longer. The milestone here is commercial, not scientific: big pharma is now publicly pitching obesity drugs as longevity drugs. That will shape research funding and consumer expectations alike — which is exactly why the evidence bar has to stay high.
Also in longevity news this week: at Toronto’s Animal Longevity Summit, Genflow Biosciences reported interim results for its SIRT6c gene therapy in 24 aged beagles — the primary endpoint was met, with treated dogs averaging about a year younger on a dog epigenetic clock at day 182 and no serious safety signals. And Life Biosciences will present first-in-human data from its Phase 1 ER-100 trial (OSK epigenetic reprogramming for optic neuropathies) on October 8 at Eyecelerator in New Orleans. Clock stories, not mitochondria stories — included here for context on the industry’s clock obsession.
Where the evidence stands
- Established: Lilly’s SURMOUNT-5 epigenetic sub-study measured less aging than elapsed time across 15 clocks (2 significant); an independent lab reproduced the direction. Duffin framed it as a methods pilot.
- Contested: That tirzepatide or semaglutide slow biological aging — the Lilly data are a small non-randomized pilot; Novo’s 3–4-year claim is unpublished and relayed secondhand.
- Absent: Direct human mitochondrial/respirometric data for GLP-1 drugs; proof that clock-slowing means real functional benefit or longer life.